An analysis of national news coverage of semaglutide for weight loss.

Background: Glucagon-like peptide 1 (GLP-1) agonists like semaglutide have risen significantly in use in recent years as a therapeutic option for the management of obesity. Popular media serves as an information source for many patients, and depending on the content, may influence how a patient views a particular therapy.

Objective: To describe the content of online/print news articles published about semaglutide for weight loss.